Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.yjmcc.2024.10.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass.
Osteoporos Int
January 2025
Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Unlabelled: We investigated the efficacy of romosozumab in premenopausal women with low bone mass. Romosozumab substantially increased bone mineral density and trabecular bone score in these women, aligning with its proven therapeutic benefits for postmenopausal osteoporosis.
Purpose: Romosozumab, an anti-sclerostin antibody, is a promising anabolic agent that increases bone formation and decreases bone resorption.
Tibial Skeletal Adaptations in Male and Female Marine Corps Officer Candidates Undergoing 10 Weeks of Military Training.
Calcif Tissue Int
January 2025
Neuromuscular Research Laboratory/Warrior Human Performance Research Center, Department of Sports Medicine and Nutrition, University of Pittsburgh, 3860 S. Water St, Pittsburgh, PA, 15203, USA.
Military training improves tibial density, structure, and estimated strength; however, men and women may adapt differently. Most work performed in military populations has assessed changes in bone health during initial entry programs, a timeframe at the beginning of a service member's career when bones may be more adaptable to a novel mechanical stimulus. The purpose of this investigation was to examine changes in tibial volumetric bone mineral density (vBMD), structure, and estimated strength, and biomarkers of bone metabolism (P1NP, osteocalcin, TRAP5b, sclerostin) between male and female candidates measured at the start and end of United States Marine Corps Officer Candidates School (OCS), a 10-week military training program attended by older service members (~ 25 y/o) who may have previous military experience.
View Article and Find Full Text PDFCorrection to: Effect of anti-sclerostin antibody on orthodontic tooth movement in ovariectomized rats.
Prog Orthod
January 2025
Institute for Innovation in Digital Healthcare (IIDH), Yonsei University Health System, Seoul, Korea.
Role of sclerostin in mastocytosis bone disease.
Sci Rep
January 2025
Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Staszica Street 11, 20-081, Poland.
Mastocytosis is a heterogeneous group of disorders, characterized by accumulation of clonal mast cells which can infiltrate several organs, most often spine (70%). The pathogenesis of mastocytosis bone disease is poorly understood. The main aim of the study was to investigate whether neoplastic mast cells may be the source of sclerostin and whether there is an association between sclerostin and selected bone remodeling markers with mastocytosis related bone disease.
View Article and Find Full Text PDFSclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly.
Front Endocrinol (Lausanne)
January 2025
Department and Clinic of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wrocław, Poland.
Article Synopsis
- Acromegaly is marked by increased bone turnover and higher vertebral fracture risk, with sclerostin inhibiting bone formation and playing a role in the OPG/RANK-L system that regulates bone metabolism.
- The study investigated levels of sclerostin, osteoprotegerin (OPG), and RANK-L in 126 patients with varying acromegaly activity, aiming to explore connections between sclerostin and bone health.
- Results showed lower sclerostin levels in acromegaly patients compared to controls, with notable differences in OPG levels across groups but no significant changes in RANK-L; a positive correlation was found between sclerostin and OPG in patients with various acromegaly
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!